Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) - January 9, 2026 Deadline to Join – Contact Levi & Korsinsky